Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2024-11-30 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 85% confidence The document is a FORM 52-109FV2 “Certification of Interim Filings” under Canadian NI 52-109, signed by the CFO, attesting to the completeness and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2024. It is not the actual interim/quarterly report (IR), nor an announcement of publication (RPA), but a mandatory regulatory certificate. This does not fit any more specific category, so it falls into the fallback category for miscellaneous regulatory filings.
2024-11-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 98% confidence The document is Form 52-109FV2, a certification by the CEO of the interim filings (interim financial report and interim MD&A) under Canadian NI 52-109. It is not the interim report itself (IR) nor is it announcing the publication of a report (RPA). It is a regulatory compliance filing that does not fit any other specific category. Therefore, it falls into the fallback category: Regulatory Filings (RNS).
2024-11-30 English
Interim MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Interim Management's Discussion and Analysis – Quarterly Highlights' for the period ended September 30, 2024. It explicitly states it is prepared in compliance with Form 51-102F1 (Continuous Disclosure Obligations) and provides a detailed discussion of business operations, liquidity, and capital resources. This is a standard quarterly management report, which falls under the 'Management Reports' category. Q1 2025
2024-11-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Revive Therapeutics Ltd. for the three months ended September 30, 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Comprehensive Loss, Statement of Cash Flows, and Statement of Changes in Shareholders' Equity) along with detailed notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. Q1 2025
2024-11-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a scientific article about a novel therapeutic approach of psilocybin in stroke. It discusses research results and intellectual property related to the company's drug development programs. There is no indication that this is a financial report, regulatory filing, or any formal corporate filing such as an annual report, earnings release, or management discussion. The document is primarily an announcement of a scientific publication and company research progress, not a financial or regulatory filing. It does not contain financial statements, voting results, or management changes. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2024-11-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Revive Therapeutics providing an update on a research study evaluating Bucillamine for nerve agent exposure. It discusses the progress and expected completion of the study, the scientific background, and potential future regulatory approvals. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The document is informational and promotional in nature, typical of a general regulatory announcement or corporate update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a certification or voting result announcement. Given the content and format, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length (5742 characters) and content confirm it is not merely a report publication announcement but a substantive update. Confidence is high due to clear exclusion of other categories and the nature of the document as a corporate update press release.
2024-10-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.